Stocks and Investing Stocks and Investing
Fri, April 14, 2023
Thu, April 13, 2023

Carter Gould Maintained (ABBV) at Hold with Increased Target to $160 on, Apr 13th, 2023


Published on 2024-10-28 02:45:00 - WOPRAI, Carter Gould
  Print publication without navigation


Carter Gould of Barclays, Maintained "AbbVie Inc." (ABBV) at Hold with Increased Target from $155 to $160 on, Apr 13th, 2023.

Carter has made no other calls on ABBV in the last 4 months.



There are 12 other peers that have a rating on ABBV. Out of the 12 peers that are also analyzing ABBV, 6 agree with Carter's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jasper Hellweg of "Argus Research" Downgraded from Strong Buy to Hold on, Wednesday, April 5th, 2023
  • Tim Anderson of "Wolfe Research" Downgraded from Buy to Hold on, Wednesday, February 22nd, 2023
  • Navin Jacob of "UBS" Maintained at Hold with Increased Target to $152 on, Friday, February 10th, 2023
  • David Risinger of "SVB Leerink" Upgraded from Sell to Hold and Increased Target to $153 on, Friday, February 10th, 2023
  • Steve Chesney of "Atlantic Equities" Maintained at Hold with Decreased Target to $154 on, Friday, February 10th, 2023
  • Geoff Meacham of "B of A Securities" Maintained at Hold with Increased Target to $165 on, Wednesday, December 14th, 2022


These are the ratings of the 6 analyists that currently disagree with Carter


  • Terence Flynn of "Morgan Stanley" Maintained at Buy with Increased Target to $181 on, Monday, April 10th, 2023
  • Vamil Divan of "Guggenheim" Initiated at Strong Buy and Held Target at $172 on, Wednesday, March 1st, 2023
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $163 on, Friday, February 10th, 2023
  • Gavin Clark-Gartner of "Evercore ISI Group" Maintained at Buy with Increased Target to $165 on, Thursday, February 9th, 2023
  • Robyn Karnauskas of "Truist Securities" Reiterated at Strong Buy and Held Target at $180 on, Thursday, February 9th, 2023
  • Gary Nachman of "BMO Capital" Maintained at Buy with Decreased Target to $167 on, Monday, February 6th, 2023
Contributing Sources